Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Yearbook of Obstetrics, Gynecology and Women's Health

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1090-798X(10)79314-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

  2010cited by this paper
• The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

  2008cited by this paper

• Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

  2024cites this paper
• Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria

  2023cites this paper
• Does CA-125 Have a Role in Early Diagnosis of Ovarian Malignancy in Non-Menopausal Women?

  2022cites this paper
• Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient’s plasma – a prospective trial

  2021cites this paper
• WFDC Protein: A Promising Diagnosis Biomarker of Ovarian Cancer

  2021cites this paper
• Correlation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital

  2020cites this paper
• Evaluation of HE4 and IGFBPs as Novel Biomarkers of Systemic Lupus Erythematosus with Lupus Nephritis

  2020cites this paper
• Role of HE4 and ROMA Score in Diagnosis of Ovarian Cancer in Egyptian Women

  2020cites this paper
• بررسی میزان صحت سطوح سرمی پیش از جراحی CA-125 وHE-4 در مرحلهبندی جراحی بیماران مبتلا به سرطان تخمدان مراجعه کننده به کلینیک زنان بیمارستان امام خمینی اهواز

  2020cites this paper
• Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses

  2019cites this paper
• Evaluation of adnexal tumours in the International Ovarian Tumor Analysis system in reference to histopathological results

  2019cites this paper
• RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population‐based study

  2018cites this paper
• Combined Human Epididymis 4 and Carbohydrate Antigen 125 Serum Protein Levels Diagnostic value in Ovarian Cancer

  2018cites this paper
• Contribution of Other Parameters to Malignancy Risk Index for Differentiation of Benign or Malignity in Adnexal Masses

  2018cites this paper
• Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?

  2018cites this paper
• The Diagnostic Value of Serum CEA, CA-125, and ROMA Index in Low-Grade Serous Ovarian Cancer

  2018cites this paper
• Significance of blood and salivary IEX‐1 expression in diagnosis of epithelial ovarian carcinoma

  2018cites this paper
• Clinico-pathological correlation of ovarian tumors and tumor like lesions with role of CA125 and HE4 as biomarkers for discrimination of benign and malignant ovarian tumors

  2018cites this paper
• Serum Tumor Markers for Preoperative Discrimination of Benign and Malignant Adnexal Masses

  2017cites this paper
• The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review

  2017cites this paper
• Immune modulation in serous epithelial ovarian cancer

  2017cites this paper
• CLINICAL UTILITY OF CA125, HE4 AND RISK OF OVARIAN MALIGNANCY ALGORITHM (ROMA) FOR EARLY DETECTION OF OVARIAN CARCINOMA

  2017cites this paper
• Molecular Biomarkers in Ovarian Carcinoma

  2017cites this paper
• Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.

  2016cites this paper
• Translational Research and Plasma Proteomic in Cancer

  2016cites this paper
• A Comparative Study of Serum Levels of HE4 and CA125 in Women with Ovarian Masses

  2016cites this paper
• Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus

  2016cites this paper
• Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience.

  2015cites this paper
• Human epididymis protein 4: factors of variation.

  2015cites this paper
• Benign Pelvic Masses Associated with Raised CA 125 Level: Radiological Pathological Correlation

  2015cites this paper
• Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.

  2015cites this paper
• M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients

  2015cites this paper
• Proteomics of ovarian cancer: functional insights and clinical applications

  2015cites this paper
• Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010

  2015cites this paper
• Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance

  2015influential citation
• Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes

  2014cites this paper
• Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.

  2014cites this paper
• Preoperative Evaluation of Risk of Ovarian Malignancy Algorithm Index in Prediction of Malignancy of Adnexal Masses

  2014cites this paper
• Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis

  2014cites this paper
• HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer

  2014cites this paper
• Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women

  2014cites this paper
• In 2014, can we do better than CA125 in the early detection of ovarian cancer?

  2014cites this paper
• Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.

  2014cites this paper
• Patient-Derived Xenografts as Pre-clinical Models of Response to Chemotherapy

  2014cites this paper
• Diagnostic value of serum human epididymis protein 4 versus carbohydrate antigen 125 in ovarian cancer

  2014cites this paper
• The Emerging Role of HE4 in the Evaluation of Advanced Epithelial Ovarian and Endometrial Carcinomas

  2014cites this paper
• Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?

  2013cites this paper
• The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer

  2013cites this paper
• The use of human epididymis protein 4 for differentiation between benign and malignant ovarian neoplasm

  2013cites this paper
• Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ

  2013influential citation
• HE4 has a High Diagnostic Value to Detect Epithelial Ovarian Cancer HE4 Memiliki Nilai Diagnostik yang Tinggi untuk Mendeteksi Keganasan Ovarium Tipe Epitel

  2013cites this paper
• Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response

  2013cites this paper
• Biomarkery epiteliálních nádorů ovaria a endometria

  2013cites this paper
• CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL

  2013cites this paper
• Biomarker Testing for Ovarian Cancer: Clinical Utility of Multiplex Assays

  2013cites this paper
• The significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer

  2013cites this paper
• Serum Protein Profile at Remission Can Accurately Assess Therapeutic Outcomes and Survival for Serous Ovarian Cancer

  2013cites this paper
• Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis.

  2012influential citation
• Differential Diagnosis of a Pelvic Mass: Improved Algorithms and Novel Biomarkers

  2012cites this paper
• Serum HE4 as a Useful Biomarker in Discriminating Ovarian Cancer From Benign Pelvic Disease

  2012cites this paper
• Multianalyte assay systems in the differential diagnosis of ovarian cancer.

  2012cites this paper
• Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women

  2012influential citation
• Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

  2012cites this paper
• Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

  2012cites this paper
• Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses.

  2012cites this paper
• Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass

  2011cites this paper
• Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.

  2011cites this paper
• HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases

  2011influential citation
• Circulating Biomarkers in the Study and Early Detection of Ovarian Cancer

  2011cites this paper
• Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population

  2011cites this paper
• Urinary Neutrophil Gelatinase-Associated Lipocalin Measured on Admission to the Intensive Care Unit Accurately Discriminates between Sustained and Transient Acute Kidney Injury in Adult Critically Ill Patients

  2011cites this paper
• Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer

  2011cites this paper
• Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass

  2011influential citation
• Serum human epididymis protein 4 ( HE 4 ) and Risk for Ovarian Malignancy Algorithm ( ROMA ) as new diagnostic and prognostic tools for epithelial ovarian cancer management

  2011cites this paper
• Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer

  2011cites this paper
• Laparoscopic management of adnexal masses.

  2011cites this paper
• The Utility of Human Epididymal Protein 4, Cancer Antigen 125, and Risk for Malignancy Algorithm in Ovarian Cancer and Endometriosis

  2011cites this paper
• Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma

  2011cites this paper
• Serum biomarker profiles as diagnostic tools in lung cancer

  2011cites this paper
• No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.

  2011cites this paper
• Diagnostic Value of Serum Kallikrein-Related Peptidases 6 and 10 Versus CA125 in Ovarian Cancer

  2011cites this paper
• Current clinical use of biomarkers for epithelial ovarian cancer

  2010cites this paper
• The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer

  2010cites this paper
• ORIGINAL ARTICLE

  2010cites this paper
• Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study

  2010cites this paper
• World Journal of Surgical Oncology Open Access Case Report Pelvic Mass Associated with Raised Ca 125 for Benign Condition: a Case Report

  year unknowncites this paper